Trials / Terminated
TerminatedNCT04446000
Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CSL730 in Healthy Adult Subjects
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CSL730 in Healthy Adult Subjects
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 52 (actual)
- Sponsor
- CSL Behring · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This phase 1, randomized, double-blind, placebo-controlled study will assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses of CSL730 administered by subcutaneous (SC) injection or SC infusion in healthy adult subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CSL730 | solution for injection and infusion |
| DRUG | Placebo | A solution matching the excipient profile of CSL730 without the active substance |
Timeline
- Start date
- 2020-09-23
- Primary completion
- 2023-03-28
- Completion
- 2023-03-28
- First posted
- 2020-06-24
- Last updated
- 2023-11-29
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT04446000. Inclusion in this directory is not an endorsement.